Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (91-100 of 198) with videos related to

Pageof 20
Sort By:
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Rheumatology and Therapy|March 13, 2022
Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower RegistryAlexis Ogdie, Kelley Myers, Carol Mansfield, et al.
Rheumatology and Therapy|October 18, 2021
Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2Vibeke Strand, Filip Van den Bosch, Roberto Ranza, et al.
Rheumatology and Therapy|December 18, 2021
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TofacitinibAra Dikranian, David Gold, Louis Bessette, et al.
Plos One|November 9, 2013
Nutrient regulation by continuous feeding removes limitations on cell yield in the large-scale expansion of Mammalian cell spheroidsBradley P Weegman, Peter Nash, Alexandra L Carlson, et al.
Lupus Science & Medicine|December 8, 2017
Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trialSomnath Bandyopadhyay, Sean E Connolly, Omar Jabado, et al.
Clinical Rheumatology|April 19, 2018
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitorsKathleen Tymms, Geoff Littlejohn, Hedley Griffiths, et al.
Arthritis Research & Therapy|January 27, 2021
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studiesBernard Combe, Tsen-Fang Tsai, J Eugene Huffstutter, et al.
Arthritis Care & Research|October 26, 2012
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label studyPeter Nash, Sauithree Nayiager, Mark C Genovese, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Pageof 20

Showing results (91-100 of 198) with videos related to

Sort By:
Pageof 20
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Rheumatology and Therapy|March 13, 2022
Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower RegistryAlexis Ogdie, Kelley Myers, Carol Mansfield, et al.
Rheumatology and Therapy|October 18, 2021
Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2Vibeke Strand, Filip Van den Bosch, Roberto Ranza, et al.
Rheumatology and Therapy|December 18, 2021
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TofacitinibAra Dikranian, David Gold, Louis Bessette, et al.
Plos One|November 9, 2013
Nutrient regulation by continuous feeding removes limitations on cell yield in the large-scale expansion of Mammalian cell spheroidsBradley P Weegman, Peter Nash, Alexandra L Carlson, et al.
Lupus Science & Medicine|December 8, 2017
Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trialSomnath Bandyopadhyay, Sean E Connolly, Omar Jabado, et al.
Clinical Rheumatology|April 19, 2018
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitorsKathleen Tymms, Geoff Littlejohn, Hedley Griffiths, et al.
Arthritis Research & Therapy|January 27, 2021
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studiesBernard Combe, Tsen-Fang Tsai, J Eugene Huffstutter, et al.
Arthritis Care & Research|October 26, 2012
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label studyPeter Nash, Sauithree Nayiager, Mark C Genovese, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Pageof 20